NICE draft guidance recommends Amgen's Xgeva for some bone metastasis patients
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance recommending the use of Amgen's human monoclonal antibody denosumab (Xgeva,) for certain groups of cancer patients with bone metastasis from solid tumours.